Fol. Biol. 2003, 49, 183-190
https://doi.org/10.14712/fb2003049050183
Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2: an Outcome Study
Individual author index pages
- Edith Huland
- A. Burger
- J. Fleischer
- P. Fornara
- E. Hatzmann
- A. Heidenreich
- H. Heinzer
- H. Heynemann
- L. Hoffmann
- R. Hofmann
- H. Huland
- I. Kämpfer
- M. Kindler
- H. Kirchner
- G. Mehlhorn
- T. H. Moniak
- U. Rebmann
- J. Roigas
- T. H. Schneider
- D. Schnorr
- H.-J. Schmitz
- R. Wenisch
- Z. Varga
- J. Vinke
Other articles of these authors
-
A Prospective Open-Label Single-Arm Phase II Study of Chimeric Monoclonal Antibody cG250 in Advanced Renal Cell Carcinoma Patients
Zoltan Varga, P. De Mulder, W. Kruit, A. Hegele, R. Hofmann, C. Lamers, S. Warnaar, C. Mala, S. Ullrich, P. Mulders
2003, Vol. 49, Issue 2, pp. 74-77 -
Interleukin-2 and Cancer - Physiological and Pharmacological Uses
Edith Huland
2001, Vol. 47, Issue 4, pp. 111-112 -
A Comparison of Systemic Versus Inhaled Recombinant IL-2 Administration for the Treatment of Metastatic Renal Cell Carcinoma
Edith Huland, H. Heinzer, H. Huland
2000, Vol. 46, Issue 6, pp. 241-250
